Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2014 Feb 11;63(5):478-80.
doi: 10.1016/j.jacc.2013.08.1639. Epub 2013 Oct 23.

New therapeutic targets for calcific aortic valve stenosis: the lipoprotein(a)-lipoprotein-associated phospholipase A2-oxidized phospholipid axis

Ming-Yow Hung  1 , Joseph L Witztum  2 , Sotirios Tsimikas  3
Affiliations
Editorial

New therapeutic targets for calcific aortic valve stenosis: the lipoprotein(a)-lipoprotein-associated phospholipase A2-oxidized phospholipid axis

Ming-Yow Hung et al. J Am Coll Cardiol. .

Abstract

Calcific aortic valve stenosis (CAVS) is the most common form of acquired valvular heart disease, present in 3% of the population more than 75 years of age (1). Although risk factors are similar for CAVS and atherosclerosis, ~50% of patients with CAVS do not have clinically significant cardiovascular disease (CVD), suggesting related, but unique, pathophysiology (1). Although surgical aortic valve replacement remains the gold standard treatment for most patients, at least one-third of symptomatic patients with CAVS may not undergo surgical aortic valve replacement.

Keywords: Lp-PLA2; aortic stenosis; calcific aortic valve disease; lysophosphatidylcholine; valve interstitial cells.

PubMed Disclaimer

Comment on

References

    1. Rajamannan NM, Evans FJ, Aikawa E, et al. Calcific aortic valve disease: not simply a degenerative process. A review and agenda for research from the National Heart and Lung and Blood Institute Aortic Stenosis Working Group. Executive summary: calcific aortic valve diseased—2011 update. Circulation. 2011;124:1783–91. - PMC - PubMed
    1. Tsimikas S, Tsironis LD, Tselepis AD. New insights into the role of lipoprotein(a)-associated lipoprotein-associated phospholipase A2 in atherosclerosis and cardiovascular disease. Arterioscler Thromb Vasc Biol. 2007;27:2094–9. - PubMed
    1. Tsimikas S, Hall JH. Lipoprotein(a) as a potential causal genetic risk factor of cardiovascular disease: a rationale for increased efforts to understand its pathophysiology and develop targeted therapies. J Am Coll Cardiol. 2012;60:716–21. - PubMed
    1. Thanassoulis G, Campbell CY, Owens DS, et al. Genetic associations with valvular calcification and aortic stenosis. N Engl J Med. 2013;368:503–12. - PMC - PubMed
    1. Spence JD, Koschinsky ML. Mechanisms of lipoprotein(a) pathogenicity. Arterioscler Thromb Vasc Biol. 2012;32:1550–1. - PubMed

Substances